Please login to the form below

Not currently logged in
Email:
Password:

HBV

This page shows the latest HBV news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Precision is pleased that initial studies with our ARCUS platform have established an important role for genome editing in their HBV program. ... We look forward to exploring this [Precision BioScience’s genome editing] technology as an important

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    The European Commission has granted Gilead's Vemlidy European marketing authorisation, making it the first new hepatitis B virus (HBV) treatment to receive EU approval in nearly a decade. ... In Europe, a WHO report from 2016 showed that 13 million

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    Gilead Sciences' once-daily chronic hepatitis B virus (HBV) therapy Vemlidy has been recommended for the treatment of adults and adolescents by the Committee for Medicinal Products for Human Use (CHMP). ... The CHMP's recommendation follows the drug's

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    Meanwhile, Gilead has also reported positive news in the area of hepatitis B virus (HBV) therapy, revealing that its tenofovir alafenamide fumarate (TAF) candidate had hit its objectives in two phase ... The trials involved treatment-naïve and

  • J&J buys firm seeking hepatitis B cure J&J buys firm seeking hepatitis B cure

    Johnson &Johnson (J&J) has agreed to buy a Pennsylvania biotech company that is trying to develop treatments to cure hepatitis B virus (HBV) infection. ... and disrupts the HBV lifecycle by inducing the assembly of defective capsids - the protein shell

  • Novartis meningitis vaccine performs well

    The vaccine was administered at 2, 4, 6 and 12 months, both alone and in combination with other paediatric vaccines (DTaP, IPV, HBV, Hib, pneumococcal).

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals in April 2015 Pharma deals in April 2015

    These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with chronic hepatitis B virus (HBV) infection.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics